{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:56:27Z","timestamp":1790790987648,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010773","name":"Demensf\u00f6rbundet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010773","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>Psychotropic medications include many drugs that may be inappropriate for older individuals with cognitive impairment. In Sweden, many people become registered in the Swedish Dementia Registry when they are diagnosed with major neurocognitive disorder (NCD). In this study, we aim to describe psychotropic drug use and associated factors among older Swedish people with major NCD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study included 38,251 people\u2009\u2265\u200965\u00a0years from the Swedish registry for cognitive\/dementia disorders diagnosed during 2007\u20132017. Drug use was defined as one or more filled prescription(s) recorded in the Swedish Prescribed Drug Register during 1 July to 31 December 2017. Associations between psychotropics and age, sex, diagnosis date, Mini-Mental State Examination score and major NCD subtype were analysed through multiple logistic regression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found that 12.0% of the individuals filled at least one prescription for antipsychotics, 22.0% for anxiolytics, 23.0% for sedatives or hypnotics, 43.2% for antidepressants and 56.7% for antidementia drugs. In brief, psychotropic use was associated with female sex, higher age, longer time since diagnosis and specific subtypes of major NCD; the strongest association was found between antipsychotics and Lewy body dementia (odds ratio 2.40, 95% confidence interval 2.04\u20132.82).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Psychotropic drugs were frequently dispensed among older Swedish people with major NCD. The use of antipsychotics and medications with sedative properties warrants concern, especially among those with Lewy body dementia who are severely sensitive to antipsychotics. A more restrictive prescribing pattern regarding these medications might reduce the risk of drug-related problems in this vulnerable group of people.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-021-03241-7","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T17:02:42Z","timestamp":1636045362000},"page":"477-487","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Psychotropic drug use among older people with major neurocognitive disorder: a cross-sectional study based on Swedish national registries"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9422-5125","authenticated-orcid":false,"given":"Jonas","family":"Kindstedt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8364-6290","authenticated-orcid":false,"given":"Maria","family":"Sj\u00f6lander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-4780","authenticated-orcid":false,"given":"Hugo","family":"L\u00f6vheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3615-4880","authenticated-orcid":false,"given":"Maria","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"issue":"1","key":"3241_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00002512-199915010-00002","volume":"15","author":"AR Moore","year":"1999","unstructured":"Moore AR, O\u2019Keeffe ST (1999) Drug-induced cognitive impairment in the elderly. Drugs Aging 15(1):15\u201328","journal-title":"Drugs Aging"},{"issue":"1","key":"3241_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SHD (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57(1):6\u201314","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3241_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1159\/000481568","volume":"7","author":"A Mukherjee","year":"2017","unstructured":"Mukherjee A, Biswas A, Roy A, Biswas S, Gangopadhyay G, Das SK (2017) Behavioural and psychological symptoms of dementia: correlates and impact on caregiver distress. Dement Geriatr Cogn Dis Extra 7(3):354\u2013365","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"7","key":"3241_CR4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0929-6646(09)60150-9","volume":"105","author":"MJ Chiu","year":"2006","unstructured":"Chiu MJ, Chen TF, Yip PK, Hua MS, Tang LY (2006) Behavioral and psychologic symptoms in different types of dementia. J Formos Med Assoc 105(7):556\u2013562","journal-title":"J Formos Med Assoc"},{"issue":"11","key":"3241_CR5","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/gps.1395","volume":"20","author":"S Engelborghs","year":"2005","unstructured":"Engelborghs S, Maertens K, Nagels G, Vloeberghs E, Marien P, Symons A et al (2005) Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. Int J Geriatr Psychiatry 20(11):1028\u20131037","journal-title":"Int J Geriatr Psychiatry"},{"issue":"2","key":"3241_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11940-012-0166-9","volume":"14","author":"A Corbett","year":"2012","unstructured":"Corbett A, Smith J, Creese B, Ballard C (2012) Treatment of behavioral and psychological symptoms of Alzheimer\u2019s disease. Curr Treat Options Neurol 14(2):113\u2013125","journal-title":"Curr Treat Options Neurol"},{"issue":"8","key":"3241_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/1756285617712979","volume":"10","author":"OP Tible","year":"2017","unstructured":"Tible OP, Riese F, Savaskan E, von Gunten A (2017) Best practice in the management of behavioural and psychological symptoms of dementia. Ther Adv Neurol Disord 10(8):297\u2013309","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"3241_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2165\/11534320-000000000-00000","volume":"30","author":"J Olsson","year":"2010","unstructured":"Olsson J, Bergman A, Carlsten A, Oke T, Bernsten C, Schmidt IK et al (2010) Quality of drug prescribing in elderly people in nursing homes and special care units for dementia: a cross-sectional computerized pharmacy register analysis. Clin Drug Investig 30(5):289\u2013300","journal-title":"Clin Drug Investig"},{"key":"3241_CR9","doi-asserted-by":"crossref","unstructured":"Gustafsson M, Karlsson S, Gustafson Y, L\u00f6vheim H (2013) Psychotropic drug use among people with dementia\u2013a six-month follow-up study. BMC Pharmacol Toxicol 14:56","DOI":"10.1186\/2050-6511-14-56"},{"issue":"7457","key":"3241_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/bmj.38125.465579.55","volume":"329","author":"PE Lee","year":"2004","unstructured":"Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA (2004) Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 329(7457):75","journal-title":"BMJ"},{"issue":"15","key":"3241_CR11","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa061240","volume":"355","author":"LS Schneider","year":"2006","unstructured":"Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS et al (2006) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease. N Engl J Med 355(15):1525\u20131538","journal-title":"N Engl J Med"},{"issue":"5","key":"3241_CR12","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jama.293.5.596","volume":"293","author":"KM Sink","year":"2005","unstructured":"Sink KM, Holden KF, Yaffe K (2005) Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293(5):596\u2013608","journal-title":"JAMA"},{"issue":"12","key":"3241_CR13","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/gps.504","volume":"16","author":"WC Chan","year":"2001","unstructured":"Chan WC, Lam LC, Choy CN, Leung VP, Li SW, Chiu HF (2001) A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 16(12):1156\u20131162","journal-title":"Int J Geriatr Psychiatry"},{"issue":"11","key":"3241_CR14","doi-asserted-by":"publisher","first-page":"775","DOI":"10.7326\/0003-4819-146-11-200706050-00006","volume":"146","author":"SS Gill","year":"2007","unstructured":"Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K et al (2007) Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 146(11):775\u2013786","journal-title":"Ann Intern Med"},{"issue":"10","key":"3241_CR15","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1001\/archinte.168.10.1090","volume":"168","author":"PA Rochon","year":"2008","unstructured":"Rochon PA, Normand SL, Gomes T, Gill SS, Anderson GM, Melo M et al (2008) Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 168(10):1090\u20131096","journal-title":"Arch Intern Med"},{"issue":"4","key":"3241_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jagp.2013.06.007","volume":"22","author":"EM Langballe","year":"2014","unstructured":"Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbaek G (2014) Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. Am J Geriatr Psychiatry 22(4):321\u2013331","journal-title":"Am J Geriatr Psychiatry"},{"key":"3241_CR17","doi-asserted-by":"crossref","unstructured":"Schwertner E, Secnik J, Garcia-Ptacek S, Johansson B, Nagga K, Eriksdotter M et al (2019) Antipsychotic treatment associated with increased mortality risk in patients with dementia. A registry-based observational cohort study. J Am Med Dir Assoc 20(3):323\u20139.e2","DOI":"10.1016\/j.jamda.2018.12.019"},{"issue":"6","key":"3241_CR18","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S0009-9236(98)90059-5","volume":"64","author":"JT Hanlon","year":"1998","unstructured":"Hanlon JT, Horner RD, Schmader KE, Fillenbaum GG, Lewis IK, Wall WE Jr et al (1998) Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther 64(6):684\u2013692","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3241_CR19","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/bcp.12596","volume":"80","author":"EA Davies","year":"2015","unstructured":"Davies EA, O\u2019Mahony MS (2015) Adverse drug reactions in special populations - the elderly. Br J Clin Pharmacol 80(4):796\u2013807","journal-title":"Br J Clin Pharmacol"},{"key":"3241_CR20","unstructured":"The National Board of Health and Welfare (2017) Indikatorer f\u00f6r god l\u00e4kemedelsterapi hos \u00e4ldre [Eng. Indicators for evaluating the quality of older people\u2019s drug therapy]. Accessed 5 August 2021. Available from: https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/ovrigt\/2017-6-7.pdf"},{"issue":"2","key":"3241_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10072-009-0033-y","volume":"30","author":"I Cancelli","year":"2009","unstructured":"Cancelli I, Beltrame M, Gigli GL, Valente M (2009) Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. Neurol Sci 30(2):87\u201392","journal-title":"Neurol Sci"},{"key":"3241_CR22","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2147\/NDT.S163842","volume":"14","author":"J Masopust","year":"2018","unstructured":"Masopust J, Protopopov\u00e1 D, Vali\u0161 M, Pavelek Z, Kl\u00edmov\u00e1 B (2018) Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review. Neuropsychiatr Dis Treat 14:1211\u20131220","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3241_CR23","unstructured":"Swedish registry for cognitive\/dementia disorders (SveDem) (2020). Annual report 2019. Accessed 1 August 2021. Available from:\u00a0https:\/\/www.ucr.uu.se\/svedem\/om-svedem\/arsrapporter\/svedem-arsrapport-2019\/viewdocument\/1000"},{"issue":"7","key":"3241_CR24","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/JGP.0b013e318167ae76","volume":"16","author":"G Selbaek","year":"2008","unstructured":"Selbaek G, Kirkevold O, Engedal K (2008) The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes\u2013a 12-month follow-up study. Am J Geriatr Psychiatry 16(7):528\u2013536","journal-title":"Am J Geriatr Psychiatry"},{"issue":"10","key":"3241_CR25","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1017\/S1041610211001438","volume":"23","author":"SU Zuidema","year":"2011","unstructured":"Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT (2011) Psychotropic drug prescription in nursing home patients with dementia: influence of environmental correlates and staff distress on physicians\u2019 prescription behavior. Int Psychogeriatr 23(10):1632\u20131639","journal-title":"Int Psychogeriatr"},{"issue":"8","key":"3241_CR26","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00228-016-2058-5","volume":"72","author":"M Gustafsson","year":"2016","unstructured":"Gustafsson M, Isaksson U, Karlsson S, Sandman PO, Lovheim H (2016) Behavioral and psychological symptoms and psychotropic drugs among people with cognitive impairment in nursing homes in 2007 and 2013. Eur J Clin Pharmacol 72(8):987\u2013994","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"3241_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jamda.2013.09.012","volume":"15","author":"B Afram","year":"2014","unstructured":"Afram B, Stephan A, Verbeek H, Bleijlevens MH, Suhonen R, Sutcliffe C et al (2014) Reasons for institutionalization of people with dementia: informal caregiver reports from 8 European countries. J Am Med Dir Assoc 15(2):108\u2013116","journal-title":"J Am Med Dir Assoc"},{"issue":"6","key":"3241_CR28","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1111\/jan.12493","volume":"71","author":"A Stephan","year":"2015","unstructured":"Stephan A, Afram B, Koskenniemi J, Verbeek H, Soto ME, Bleijlevens MH et al (2015) Older persons with dementia at risk for institutionalization in eight European countries: a cross-sectional study on the perceptions of informal caregivers and healthcare professionals. J Adv Nurs 71(6):1392\u20131404","journal-title":"J Adv Nurs"},{"issue":"1","key":"3241_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.euroneuro.2013.09.003","volume":"24","author":"A Gallini","year":"2014","unstructured":"Gallini A, Andrieu S, Donohue JM, Oumouhou N, Lapeyre-Mestre M, Gardette V (2014) Trends in use of antipsychotics in elderly patients with dementia: impact of national safety warnings. Eur Neuropsychopharmacol 24(1):95\u2013104","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"3241_CR30","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s40264-017-0538-x","volume":"40","author":"SJ Stocks","year":"2017","unstructured":"Stocks SJ, Kontopantelis E, Webb RT, Avery AJ, Burns A, Ashcroft DM (2017) Antipsychotic prescribing to patients diagnosed with dementia without a diagnosis of psychosis in the context of national guidance and drug safety warnings: longitudinal study in UK general practice. Drug Saf 40(8):679\u2013692","journal-title":"Drug Saf"},{"issue":"3","key":"3241_CR31","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/0706743716673321","volume":"62","author":"J Kirkham","year":"2017","unstructured":"Kirkham J, Sherman C, Velkers C, Maxwell C, Gill S, Rochon P et al (2017) Antipsychotic use in dementia. Can J Psychiatry 62(3):170\u2013181","journal-title":"Can J Psychiatry"},{"issue":"1","key":"3241_CR32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12877-018-0740-4","volume":"18","author":"I Zahirovic","year":"2018","unstructured":"Zahirovic I, Torisson G, Wattmo C, Londos E (2018) Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a cross-sectional study in 40 nursing homes in Sweden. BMC Geriatr 18(1):50","journal-title":"BMC Geriatr"},{"issue":"5\u20136","key":"3241_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000348408","volume":"35","author":"K Johnell","year":"2013","unstructured":"Johnell K, Religa D, Eriksdotter M (2013) Differences in drug therapy between dementia disorders in the Swedish dementia registry: a nationwide study of over 7,000 patients. Dement Geriatr Cogn Disord 35(5\u20136):239\u2013248","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"5","key":"3241_CR34","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/gps.389","volume":"16","author":"D Aarsland","year":"2001","unstructured":"Aarsland D, Ballard C, Larsen JP, McKeith I (2001) A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson\u2019s disease with and without dementia. Int J Geriatr Psychiatry 16(5):528\u2013536","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6855","key":"3241_CR35","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/bmj.305.6855.673","volume":"305","author":"I McKeith","year":"1992","unstructured":"McKeith I, Fairbairn A, Perry R, Thompson P, Perry E (1992) Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 305(6855):673\u2013678","journal-title":"BMJ"},{"issue":"12","key":"3241_CR36","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"IG McKeith","year":"2005","unstructured":"McKeith IG, Dickson DW, Lowe J, Emre M, O\u2019Brien JT, Feldman H et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12):1863\u20131872","journal-title":"Neurology"},{"issue":"5","key":"3241_CR37","doi-asserted-by":"publisher","first-page":"633","DOI":"10.4088\/JCP.v66n0514","volume":"66","author":"D Aarsland","year":"2005","unstructured":"Aarsland D, Perry R, Larsen JP, McKeith IG, O\u2019Brien JT, Perry EK et al (2005) Neuroleptic sensitivity in Parkinson\u2019s disease and parkinsonian dementias. J Clin Psychiatry 66(5):633\u2013637","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"3241_CR38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jamaneurol.2016.0031","volume":"73","author":"D Weintraub","year":"2016","unstructured":"Weintraub D, Chiang C, Kim HM, Wilkinson J, Marras C, Stanislawski B et al (2016) Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol 73(5):535\u2013541","journal-title":"JAMA Neurol"},{"issue":"9","key":"3241_CR39","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2165\/00002018-200326090-00004","volume":"26","author":"HH Fernandez","year":"2003","unstructured":"Fernandez HH, Trieschmann ME, Friedman JH (2003) Treatment of psychosis in Parkinson\u2019s disease: safety considerations. Drug Saf 26(9):643\u2013659","journal-title":"Drug Saf"},{"issue":"1","key":"3241_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mdc3.12383","volume":"4","author":"MJ Armstrong","year":"2017","unstructured":"Armstrong MJ, Weintraub D (2017) The case for antipsychotics in dementia with Lewy bodies. Mov Disord Clin Pract 4(1):32\u201335","journal-title":"Mov Disord Clin Pract"},{"issue":"3","key":"3241_CR41","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1017\/S1041610209008497","volume":"21","author":"H L\u00f6vheim","year":"2009","unstructured":"L\u00f6vheim H, Sandman PO, Karlsson S, Gustafson Y (2009) Sex differences in the prevalence of behavioral and psychological symptoms of dementia. Int Psychogeriatr 21(3):469\u2013475","journal-title":"Int Psychogeriatr"},{"issue":"1\u20132","key":"3241_CR42","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.psychres.2014.06.006","volume":"220","author":"G Vittadini","year":"2014","unstructured":"Vittadini G, Beghi M, Mezzanzanica M, Ronzoni G, Cornaggia CM (2014) Use of psychotropic drugs in Lombardy in time of economic crisis (2007\u20132011): a population-based study of adult employees. Psychiatry Res 220(1\u20132):615\u2013622","journal-title":"Psychiatry Res"},{"issue":"6","key":"3241_CR43","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.eurpsy.2015.05.001","volume":"30","author":"A Boyd","year":"2015","unstructured":"Boyd A, Van de Velde S, Pivette M, Ten Have M, Florescu S, O\u2019Neill S et al (2015) Gender differences in psychotropic use across Europe: results from a large cross-sectional, population-based study. Eur Psychiatry 30(6):778\u2013788","journal-title":"Eur Psychiatry"},{"issue":"3","key":"3241_CR44","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/13607863.2018.1539834","volume":"24","author":"K Inamura","year":"2020","unstructured":"Inamura K, Shinagawa S, Tsuneizumi Y, Nagata T, Tagai K, Nukariya K et al (2020) Sex differences in the severity of neuropsychiatric symptoms and their relationship with clinico-demographic and psychosocial factors in patients with amnestic mild cognitive impairment and mild Alzheimer\u2019s disease. Aging Ment Health 24(3):431\u2013438","journal-title":"Aging Ment Health"},{"key":"3241_CR45","doi-asserted-by":"crossref","unstructured":"Xing Y, Tang Y, Jia J (2015) Sex differences in neuropsychiatric symptoms of Alzheimer\u2019s disease: the modifying effect of apolipoprotein E \u03b54 status. Behav Neurol 2015:275256","DOI":"10.1155\/2015\/275256"},{"issue":"11","key":"3241_CR46","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1089\/jwh.2017.6420","volume":"27","author":"D Colombo","year":"2018","unstructured":"Colombo D, Caltagirone C, Padovani A, Sorbi S, Spalletta G, Simoni L et al (2018) Gender differences in neuropsychiatric symptoms in mild to moderate Alzheimer\u2019s disease patients undergoing switch of cholinesterase inhibitors: a post hoc analysis of the EVOLUTION Study. J Womens Health (Larchmt) 27(11):1368\u20131377","journal-title":"J Womens Health (Larchmt)"},{"key":"3241_CR47","unstructured":"Swedish Medical Products Agency (2008) L\u00e4kemedelsbehandling och bem\u00f6tande vid Beteendem\u00e4ssiga och Psykiska Symptom vid Demenssjukdom\u2014BPSD [Eng. Pharmacological treatment and management of behavioural and psychological symptoms of dementia\u2014BPSD]. Information from the Swedish medical products Agency"},{"issue":"5","key":"3241_CR48","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s40266-014-0165-5","volume":"31","author":"B Hovstadius","year":"2014","unstructured":"Hovstadius B, Petersson G, Hellstr\u00f6m L, Ericson L (2014) Trends in inappropriate drug therapy prescription in the elderly in Sweden from 2006 to 2013: assessment using national indicators. Drugs Aging 31(5):379\u2013386","journal-title":"Drugs Aging"},{"issue":"1","key":"3241_CR49","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12877-017-0530-4","volume":"17","author":"NW Yu","year":"2017","unstructured":"Yu NW, Chen PJ, Tsai HJ, Huang CW, Chiu YW, Tsay WI et al (2017) Association of benzodiazepine and Z-drug use with the risk of hospitalisation for fall-related injuries among older people: a nationwide nested case-control study in Taiwan. BMC Geriatr 17(1):140","journal-title":"BMC Geriatr"},{"issue":"12","key":"3241_CR50","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1111\/j.1532-5415.2001.49280.x","volume":"49","author":"PS Wang","year":"2001","unstructured":"Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J (2001) Zolpidem use and hip fractures in older people. J Am Geriatr Soc 49(12):1685\u20131690","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"3241_CR51","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/gerona\/60.5.622","volume":"60","author":"F Landi","year":"2005","unstructured":"Landi F, Onder G, Cesari M, Barillaro C, Russo A, Bernabei R (2005) Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. J Gerontol A Biol Sci Med Sci 60(5):622\u2013626","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"6","key":"3241_CR52","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/ageing\/aft089","volume":"42","author":"OJ de Vries","year":"2013","unstructured":"de Vries OJ, Peeters G, Elders P, Sonnenberg C, Muller M, Deeg DJ et al (2013) The elimination half-life of benzodiazepines and fall risk: two prospective observational studies. Age Ageing 42(6):764\u2013770","journal-title":"Age Ageing"},{"issue":"4","key":"3241_CR53","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.maturitas.2013.01.004","volume":"74","author":"AM van Strien","year":"2013","unstructured":"van Strien AM, Koek HL, van Marum RJ, Emmelot-Vonk MH (2013) Psychotropic medications, including short acting benzodiazepines, strongly increase the frequency of falls in elderly. Maturitas 74(4):357\u2013362","journal-title":"Maturitas"},{"key":"3241_CR54","doi-asserted-by":"crossref","unstructured":"Martinez C, Jones RW, Rietbrock S (2013) Trends in the prevalence of antipsychotic drug use among patients with Alzheimer\u2019s disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open\u00a03(1)","DOI":"10.1136\/bmjopen-2012-002080"},{"issue":"2","key":"3241_CR55","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.maturitas.2014.05.009","volume":"79","author":"S Bennett","year":"2014","unstructured":"Bennett S, Thomas AJ (2014) Depression and dementia: cause, consequence or coincidence? Maturitas 79(2):184\u2013190","journal-title":"Maturitas"},{"key":"3241_CR56","doi-asserted-by":"crossref","unstructured":"Leth-Moller KB, Hansen AH, Torstensson M, Andersen SE, Odum L, Gislasson G et al (2016) Antidepressants and the risk of hyponatremia: a Danish register-based population study. BMJ Open\u00a06(5):e011200","DOI":"10.1136\/bmjopen-2016-011200"},{"issue":"3","key":"3241_CR57","first-page":"1611","volume":"17","author":"YH Meng","year":"2019","unstructured":"Meng YH, Wang PP, Song YX, Wang JH (2019) Cholinesterase inhibitors and memantine for Parkinson\u2019s disease dementia and Lewy body dementia: a meta-analysis. Exp Ther Med 17(3):1611\u20131624","journal-title":"Exp Ther Med"},{"key":"3241_CR58","doi-asserted-by":"crossref","unstructured":"Matsunaga S, Kishi T, Yasue I, Iwata N (2015) Cholinesterase inhibitors for Lewy body disorders: a meta-analysis. Int J Neuropsychopharmacol 19(2)","DOI":"10.1093\/ijnp\/pyv086"},{"key":"3241_CR59","doi-asserted-by":"crossref","unstructured":"Rolinski M, Fox C, Maidment I, McShane R (2012) Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson\u2019s disease dementia and cognitive impairment in Parkinson\u2019s disease. Cochrane Database Syst Rev\u00a0(3):Cd006504","DOI":"10.1002\/14651858.CD006504.pub2"},{"key":"3241_CR60","unstructured":"Swedish registry for cognitive\/dementia disorders (SveDem) (2018) Annual report 2017. Accessed 30 July 2021. Available at: https:\/\/www.ucr.uu.se\/svedem\/om-svedem\/arsrapporter\/svedem-arsrapport-2017\/viewdocument\/828"},{"issue":"1","key":"3241_CR61","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","volume":"9","author":"M Prince","year":"2013","unstructured":"Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP (2013) The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 9(1):63-75.e2","journal-title":"Alzheimers Dement"},{"issue":"1","key":"3241_CR62","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13195-018-0350-6","volume":"10","author":"JPM Kane","year":"2018","unstructured":"Kane JPM, Surendranathan A, Bentley A, Barker SAH, Taylor JP, Thomas AJ et al (2018) Clinical prevalence of Lewy body dementia. Alzheimers Res Ther 10(1):19","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"3241_CR63","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/mds.20527","volume":"20","author":"D Aarsland","year":"2005","unstructured":"Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson\u2019s disease. Mov Disord 20(10):1255\u20131263","journal-title":"Mov Disord"},{"issue":"4","key":"3241_CR64","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1017\/S0033291713000494","volume":"44","author":"SA Vann Jones","year":"2014","unstructured":"Vann Jones SA, O\u2019Brien JT (2014) The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med 44(4):673\u2013683","journal-title":"Psychol Med"},{"issue":"3","key":"3241_CR65","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1345\/aph.1Q597","volume":"46","author":"Y Haasum","year":"2012","unstructured":"Haasum Y, Fastbom J, Johnell K (2012) Institutionalization as a risk factor for inappropriate drug use in the elderly: a Swedish nationwide register-based study. Ann Pharmacother 46(3):339\u2013346","journal-title":"Ann Pharmacother"},{"key":"3241_CR66","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.2147\/CIA.S146613","volume":"12","author":"JM Cousins","year":"2017","unstructured":"Cousins JM, Bereznicki LR, Cooling NB, Peterson GM (2017) Prescribing of psychotropic medication for nursing home residents with dementia: a general practitioner survey. Clin Interv Aging 12:1573\u20131578","journal-title":"Clin Interv Aging"},{"issue":"3","key":"3241_CR67","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1017\/S1041610213002019","volume":"26","author":"BC Kleijer","year":"2014","unstructured":"Kleijer BC, van Marum RJ, Frijters DH, Jansen PA, Ribbe MW, Egberts AC et al (2014) Variability between nursing homes in prevalence of antipsychotic use in patients with dementia. Int Psychogeriatr 26(3):363\u2013371","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"3241_CR68","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/intqhc\/mzm011","volume":"19","author":"S Wamala","year":"2007","unstructured":"Wamala S, Merlo J, Bostrom G, Hogstedt C, Agren G (2007) Socioeconomic disadvantage and primary non-adherence with medication in Sweden. Int J Qual Health Care 19(3):134\u2013140","journal-title":"Int J Qual Health Care"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03241-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03241-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03241-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T08:03:59Z","timestamp":1660550639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03241-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["3241"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03241-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"assertion":[{"value":"13 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Missing Open Access funding information has been added in the Funding Note.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethical Review Board in Ume\u00e5 approved this study (registration number 2017-256-31\u00a0M).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Hugo L\u00f6vheim is a member of the steering committee of the Swedish registry for cognitive\/dementia disorders (SveDem). The other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}